Study design, protocols and statistical analysis plans
- Protocol statistical sections: objectives, endpoints, estimands and analysis populations
- Sample size and statistical power calculations, with documented assumptions and sensitivity analyses
- Statistical analysis plans (SAPs), including table, listing and figure (TLF) shells
- Randomization and stratification specifications
- Simulation studies to compare designs and operating characteristics
- Missing data, intercurrent events and sensitivity analyses
Interim analyses and Type I error control
- Efficacy and futility interim analyses for time-to-event, binary and continuous endpoints
- Safety monitoring plans and interim safety analyses
- Group sequential designs with alpha-spending functions (O'Brien-Fleming-type, Pocock-type and Lan-DeMets approaches)
- Multiplicity control across endpoints, doses and subgroups: fixed-sequence, Bonferroni, Holm, Hochberg, gatekeeping and graphical approaches
- Adaptive designs: sample size re-estimation, population enrichment, seamless phase transitions
- Bayesian monitoring and decision rules
- DMC/DSMB charters, analysis plans and unblinded reporting packages
Therapeutic areas
- Oncology: progression-free and overall survival, response endpoints, restricted mean survival time, non-proportional hazards, basket, umbrella and platform designs
- Hematology: response and durability endpoints, transfusion and bleeding-rate outcomes, small-population designs
- Gene therapy: small-sample designs, durability of effect, long-term follow-up and natural-history comparisons
- Rare diseases: efficient designs for very small populations, external and historical controls, Bayesian borrowing
- Cardiovascular and medical devices: non-inferiority and superiority designs, performance goals, Bayesian device trials, composite endpoints
- Neurological conditions: longitudinal and repeated-measures analyses, disease-progression endpoints, responder analyses
Regulatory submission support
- Statistical support for BLA, MAA and other marketing applications
- Integrated summary of safety (ISS) and integrated summary of efficacy (ISE): analysis plans, pooling strategy and outputs
- Statistical sections of clinical study reports and submission documents
- Meeting packages and briefing documents for regulatory interactions
- Responses to regulatory questions that need statistical analyses or justification
Data standards and programming
- SDTM and ADaM datasets, including ADSL and analysis datasets for efficacy and safety
- Define-XML, annotated case report forms and reviewer's guides
- Dataset and specification validation, including Pinnacle 21 review and issue resolution
- Tables, listings and figures programming in R and SAS
- Independent QC and double programming
- Validation of existing programs and reproducible, documented workflows
Pharmacometrics and model-informed drug development
- PK/PD analyses: noncompartmental, compartmental and population approaches
- Exposure-response analyses
- PBPK model building, evaluation and simulation
- Model-informed drug development (MIDD) analyses that support dose selection and development decisions
- Quantitative systems pharmacology (QSP) modeling and simulation
How we work: Our work supports analysis and decision-making. We do not provide medical advice, and regulatory outcomes depend on many factors beyond any statistical analysis. Work begins only after the scope, timeline and terms are agreed in writing.